55 related articles for article (PubMed ID: 38640349)
1. Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia.
Park D; Chan-Golston AM; Yan Y; Al-Manaseer F; Akhtari M
J Chemother; 2024 May; ():1-12. PubMed ID: 38803142
[TBL] [Abstract][Full Text] [Related]
2. Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.
Mouhssine S; Maher N; Kogila S; Cerchione C; Martinelli G; Gaidano G
Hematol Rep; 2024 Apr; 16(2):270-282. PubMed ID: 38804280
[TBL] [Abstract][Full Text] [Related]
3. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Jurczak W; Elmusharaf N; Fox CP; Townsend W; Paulovich AG; Whiteaker JR; Krantz F; Wun CC; Parr G; Sharma S; Munugalavadla V; Manwani R; Dean E; Munir T
Ther Adv Hematol; 2023; 14():20406207231173489. PubMed ID: 37273420
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
6. Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Ghia P; Pluta A; Wach M; Lysak D; Šimkovič M; Kriachok I; Illés Á; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery EJ; Lee JH; Usenko G; Wang MH; Yu T; Jurczak W
Hemasphere; 2022 Dec; 6(12):e801. PubMed ID: 36398134
[TBL] [Abstract][Full Text] [Related]
7. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials.
Davids MS; Sharman JP; Ghia P; Woyach JA; Eyre TA; Jurczak W; Siddiqi T; Palhares de Miranda PA; Shahkarami M; Butturini AM; Emeribe U; Byrd JC
Blood Adv; 2024 Apr; ():. PubMed ID: 38640349
[TBL] [Abstract][Full Text] [Related]
8. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
9. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
Delgado J; Josephson F; Camarero J; Garcia-Ochoa B; Lopez-Anglada L; Prieto-Fernandez C; van Hennik PB; Papadouli I; Gisselbrecht C; Enzmann H; Pignatti F
Oncologist; 2021 Mar; 26(3):242-249. PubMed ID: 33486852
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
11. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
